Immune response enhancement by in vivo administration of B7.2Ig, a soluble costimulatory protein

Clinical Immunology

Volumn 92, Issue 3, 1999, Pages 235-245

  Swiniarski, Holly ^a   Sturmhoefel, Knut ^a   Lee, Kwang ^a   Gray, Gary S ^a   Thomas, Jenifer L ^a   Wolf, Stanley F ^a   Dorner, Andrew J ^a   O'Toole, Margot ^a  

^a PFIZER INC   (United States)

Author keywords

Costimulatory molecules; Peptide; Vaccination

Indexed keywords

CD86 ANTIGEN; HYBRID PROTEIN; PEPTIDE; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CANCER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HELPER CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE ACTIVATION; VACCINATION;

EID: 0032857784     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.1999.4761     Document Type: Article

References (78)

1. Boussiotis, V. A., Freeman, G. J., Gribben, J. G., and Nadler, L. M., The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response. Immunol. Rev. 153, 5-26, 1996.
2. Lenschow, D. J., Walunas, T. L., and Bluestone, J. A., CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14, 233-258, 1996.
3. Shahinian, A., Pfeffer, K., Lee, K. P., Kundig, T. M., Kishihara, K., Wakeham, A., Kawai, K., Ohashi, P. S., Thompson, C. B., and Mak, T. W., Differential T cell costimulatory requirements in CD28-deficient mice. Science 261, 609-612, 1993.
4. Green, J. M., Noel, P. J., Sperling, A. I., Walunas, T. L., Gray, G. S., Bluestone, J. A., and Thompson, C. B., Absence of B7-dependent responses in CD28-deficient mice. Immunity 1, 501-508, 1994.
5. Linsley, P. S., Brady, W., Grosmaire, L., Aruffo, A., Damle, N. K., and Ledbetter, J. A., Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 173, 721-730, 1991.
6. Harding, F. A., and Allison, J. P., CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J. Exp. Med. 177, 1791-1796, 1993.
7. Azuma, M., Cayabyab, M., Buck, D., Phillips, J. H., and Lanier, L. L., CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes. J. Exp. Med. 175, 353-360, 1992.
8. Gajewski, T. F., B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro. J. Immunol. 156, 465-472, 1996.
9. Brunet, J. F., Denizot, F., Luciani, M. F., Roux-Dosseto, M., Suzan, M., Mattei, M. G., and Golstein, P., A new member of the immunoglobulin superfamily - CTLA-4. Nature 328, 267-270, 1987.
10. Gribben, J. G., Freeman, G. J., Boussiotis, V. A., Rennert, P., Jellis, C. L., Greenfield, E., Barber, M., Restivo, V. A., Ke, X., Gray, G. S., and Nadler, L. M., CTLA4 mediates antigen-specific apoptosis of human T cells. Proc. Natl. Acad. Sci. USA 92, 811-815, 1995.
11. Kearney, E. R., Walunas, T. L., Karr, R. W., Morton, P. A., Loh, D. Y., Bluestone, J. A., and Jenkins, M. K., Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J. Immunol. 155, 1032-1036, 1995.
12. Krummel, M. F., and Allison, J. P., CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182, 459-465, 1995.
13. Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., and Bluestone, J. A., CTLA-4 can function as a negative regulator of T cell activation. Immunity 1, 405-413, 1994.
14. Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., and Sharpe, A. H., Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3, 541-547, 1995.
15. Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., and Mak, T. W., Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270, 985-988, 1995.
16. Murphy, M. L., Cotterell, S. E., Gorak, P. M., Engwerda, C. R., and Kaye, P. M., Blockade of CTLA-4 enhances host resistance to the intracellular pathogen, Leishmania donovani. J. Immunol. 161, 4153-4160, 1998.
17. Allison, J. P., CD28-B7 interactions in T-cell activation. Curr. Opin. Immunol. 6, 414-419, 1994.
18. Leach, D. R., Krummel, M. F., and Allison, J. P., Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734-1736, 1996.
19. Khoury, S. J., Akalin, E., Chandraker, A., Turka, L. A., Linsley, P. S., Sayegh, M. H., and Hancock, W. W., CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J. Immunol. 155, 4521-4524, 1995.
20. Kuchroo, V. K., Das, M. P., Brown, J. A., Ranger, A. M., Zamvil, S. S., Sobel, R. A., Weiner, H. L., Nabavi, N., and Glimcher, L. H., B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80, Mar 10(15), 1995.
21. Lenschow, D. J., Ho, S. C., Sattar, H., Rhee, L., Gray, G., Nabavi, N., Herold, K. C., and Bluestone, J. A., Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181, 1145-1155, 1995.
22. Lenschow, D. J., Zeng, Y., Thistlethwaite, J. R., Montag, A., Brady, W., Gibson, M. G., Linsley, P. S., and Bluestone, J. A., Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 257, 789-792, 1992.
23. Finck, B. K., Linsley, P. S., and Wofsy, D., Treatment of murine lupus with CTLA4Ig. Science 265, 1225-1227, 1994.
24. Kim, J. J., Bagarazzi, M. L., Trivedi, N., Hu, Y., Kazahaya, K., Wilson, D. M., Ciccarelli, R., Chattergoon, M. A., Dang, K., Mahalingam, S., Chalian, A. A., Agadjanyan, M. G., Boyer, J. D., Wang, B., and Weiner, D. B., Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nature Biotechnol. 15, 641-646, 1997.
25. Kim, J. J., Nottingham, L. K., Wilson, D. M., Bagarazzi, M. L., Tsai, A., Morrison, L. D., Javadian, A., Chalian, A. A., Agadjanyan, M. G., and Weiner, D. B., Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes. Vaccine 16, 1828-1835, 1998.
26. Baskar, S., Nabavi, N., Glimcher, L. H., and Ostrand-Rosenberg, S., Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunity. J. Immunother. 14, 209-215, 1993.
27. Baskar, S., Ostrand-Rosenberg, S., Nabavi, N., Nadler, L. M., Freeman, G. J., and Glimcher, L. H., Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA 90, 5687-5690, 1993.
28. Cavallo, F., Martin-Fontecha, A., Bellone, M., Heltai, S., Gatti, E., Tornaghi, Paola, Freshci, M., Forni, G., Dellabona, P., and Casorati, G., Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur. J. Immunol. 25, 1154-1162, 1995.
29. Coughlin, C. M., Wysocka, M., Kurzawa, H. L., Lee, W. M. F., Trinchieri, G., and Eck, S. L., B7-1 and interleukin-12 synergistically induce effective anti-tumor immunity. Cancer Res. 55, 4980-4987, 1995.
30. Chen, L., Ashe, S., Brady, W. A., Hellstrom, I., Hellstrom, K. E., Ledbetter, J. A., McGowan, P., and Linsley, P. S., Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71, 1093-1102, 1992.
31. Chen, L., McGowan, P., Ashe, S., Johnston, J., Li, Y., Hellstrom, I., and Hellstrom, K. E., Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179, 523-532, 1994.
32. Gajewski, T. F., Fallarino, F., Uyttenhove, C., and Boon, T., Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J. Immunol. 8, 2909-2917, 1996.
33. Yang, G., Hellstrom, K. E., Hellstrom, I., and Chen, L., Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J. Immunol. 154, 2794-2800, 1995.
34. Chamberlain, R. S., Carroll, M. W., Bronte, V., Hwu, P., Warren, S., Yang, J. C., Nishimura, M., Moss, B., Rosenberg, S. A., and Restifo, N. P., Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res. 56, 2832-2836, 1996.
35. Emtage, P. C., Wan, Y., Bramson, J. L., Graham, F. L., and Gauldie, J., A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model. J. Immunol. 160, 2531-2538, 1998.
36. Hodge, J. W., Abrams, S., Schlom, J., and Kantor, J. A., Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res. 54, 5552-5555, 1994.
37. Putzer, B. M., Hitt, M., Muller, W. J., Emtage, P., Gauldie, J., and Graham, F. L., Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc. Natl. Acad. Sci. USA 94, 10889-10894, 1997.
38. Rao, J. B., Chamberlain, R. S., Bronte, V., Carrol, M. W., Irvine, K. R., Moss, B., Rosenberg, S. A., and Restifo, N. P., Interleukin-12 in an effective adjuvant to recombinant vaccinia virus based tumor vaccines: Enhancement by simultaneous B7-1 expression. J. Immunol. 156, 3357-3365, 1996.
39. Boussiotis, V. A., Freeman, G. J., Gribben, J. G., Daley, J., Gray, G., and Nadler, L. M., Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation. Proc. Natl. Acad. Sci. USA 90, 11059-11063, 1993.
40. Freeman, G. J., Gribben, J. G., Boussiotis, V. A., Ng, J. W., Restivo, V. A., Lombard, L. A., Gray, G. S., and Nadler, L. M., Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262, 909-911, 1993.
41. Hathcock, K. S., Laszlo, G., Pucillo, C., Linsley, P., and Hodes, R. J., Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. 180, 631-640, 1994.
42. Chen, C., and Nabavi, N., In vitro induction of T cell anergy by blocking B7 and early T cell costimulatory molecule ETC-1/B7-2. Immunity 1, 147-154, 1994.
43. Taylor, P. M., Davey, J., Howland, K., Rothbard, J. B., and Askonas, B. A., Class I MHC molecules rather than other mouse genes dictate influenza epitope recognition by cytotoxic T cells. Immunogenetics 26, 267-272, 1987.
44. Brett, S. J., Gao, X.-M., Liew, F. Y., and Tite, J. P., Selection of the same major T cell determinants of influenza nucleoprotein after vaccination or exposure to infectious virus. J. Immunol. 147, 1647-1652, 1991.
45. Bucher, D. J., Mikhail, A., Popple, S., Graves, P., Meiklejohn, G., Hodes, D. S., Johansson, K., and Halonen, P. E., Rapid detection of type A influenza viruses with monoclonal antibodies to the M protein (M1) by enzyme-linked immunosorbent assay and time-resolved fluoroimmunoassay. J. Clin. Microbiol. 29, 2484-2488, 1991.
46. Fields, P. E., Finch, R. J., Gray, G. S., Zollner, R., Thomas, J. L., Sturmhoefel, K., Lee, K., Wolf, S., Gajewski, T. F., and Fitch, F. W., B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells. J. Immunol. 161, 5268-5275, 1998.
47. Kaufman, R. J., Wasley, L. C., and Dorner, A. J., Synthesis, processing and secretion of recombinant human factor VIII expressed in mammalian cells. J. Biol. Chem. 263, 6352-6362, 1988.
48. Van Pel, A., De Plaen, E., and Boon, T., Selection of highly transfectable variant from mouse mastocytoma P815. Somat. Cell. Mol. Genet. 11, 467-475, 1985.
49. Brett, S. J., and Tite, J. P., Both H-2- and non-H-2-linked genes influence influenza nucleoprotein epitope recognition by CD4+ T cells. Immunology 87, 42-48, 1996.
50. Fayolle, C., Deriud, E., and Leclerc, C., In vivo induction of cytotoxic T cell response by a free synthetic peptide requires CD4+ T cell help. J. Immunol. 147, 4069-4073, 1991.
51. Keene, J. A., and Forman, J., Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J. Exp. Med. 155, 768-782, 1982.
52. von Herrath, M. G., Yokoyama, M., Dockter, J., Oldstone, M. B., and Whitton, J. L., CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J. Virol. 70, 1072-1079, 1996.
53. Ossendorp, F., Mengede, E., Camps, M., Filius, R., and Melief, C. J. M., Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against mamor histocompatibility complex class II negative tumors. J. Exp. Med. 187, 693-702, 1998.
54. Aprile, M. A., and Wardlaw, A. C., Aluminium compounds as adjuvants for vaccines and toxoids in man: A review. Can. J. Pub. Health 57, 343-360, 1966.
55. Dunussi-Joannopoulos, K., Weinstein, H. J., Nickerson, P. W., Strom, T. B., Burakoff, S. J., Croop, J. M., and Arceci, R. J., Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood 87, 2938-2946, 1996.
56. Horspool, J. H., Perrin, P. J., Woodcock, J. B., Cox, J. H., King, C. L., June, C. H., Harlan, D. M., St. Louis, D. C., and Lee, K. P., Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4. J. Immunol. 160, 2706-2714, 1998.
57. Corry, D. B., Reiner, S. L., Linsley, P. S., and Locksley, R. M., Differential effects of blockade of CD28-B7 on the development of Th1 or Th2 effector cells in experimental leishmaniasis. J. Immunol. 153, 4142-4148, 1994.
58. Freeman, G. J., Boussiotis, V. A., Anumanthan, A., Bernstein, G. M., Ke, X. Y., Rennert, P. D., Gray, G. S., Gribben, J. G., and Nadler, L. M., B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 2, 523-532, 1995.
59. Schweitzer, A. N., Borriello, F., Wong, R. C., Abbas, A. K., and Sharpe, A. H., Role of costimulators in T cell differentiation: studies using antigen-presenting cells lacking expression of CD80 or CD86. J. Immunol. 158, 713-722, 1997.
60. Rulifson, I. C., Sperling, A. I., Fields, P. E., Fitch, F. W., and Bluestone, J. A., CD28 costimulation promotes the production of Th2 cytokines. J. Immunol. 158, 658-665, 1997.
61. McAdam, A. J., Schweitzer, A. N., and Sharpe, A. H., The role of B7 co-stimulation in activation and differentiation of CD4+ and CD8+ T cells. Immunol. Rev. 165, 231-247, 1998.
62. Lawson, C. M., Bennink, J. R., Restifo, N. P., Yewdell, J. W., and Murphy, B. R., Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge. J. Virol. 68, 3505-3511, 1994.
63. Jankovic, D., Caspar, P., Zweig, M., Garcia-Moll, M., Showalter, S. D., Vogel, F. R., and Sher, A., Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120. J. Immunol. 159, 2409-2417, 1997.
64. Zinkernagel, R. M., and Doherty, P. C., MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv. Immunol. 27, 51-177, 1979.
65. van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., and Boon, T., A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643-1647, 1991.
66. Wolfel, T., Hauer, M., Klehmann, E., Brichard, V., Ackermann, B., Knuth, A., Boon, T., and Meyer zum Buschenfelde, K.-H., Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL). Int. J. Cancer 55, 237-244, 1993.
67. Maeurer, M. J., Storkus, W. J., Kirkwood, J. M., and Lotze, M. T., New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res. 6, 11-24, 1996.
68. Cormier, J. N., Salgaller, M. L., Prevette, T., Barracchini, K. C., Rivoltini, L., Restifo, N. P., Rosenberg, S. A., and Marincola, F., Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J. Sci. Am. 3, 37-44, 1997.
69. Apostolopoulos, V., Karanikas, V., Haurum, J. S., and McKenzie, I. F. C., Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J. Immunol. 159, 5211-5218, 1997.
70. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H., and White, D. E., Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4, 321-327, 1998.
71. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Reinhad, D., Burg, G., and Shadendorf, D., Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature Med. 4, 328-332, 1998.
72. Allsopp, C. E. M., Plebanski, M., Gilbert, S., Sinden, R. E., Harris, S., Frankel, G., Dougan, G., Hioe, C., Nixon, D., Paoletti, E., Layton, G., and Hill, A. V. S., Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. Eur. J. Immunol. 26, 1951-1959, 1996.
73. Rotzschke, O., Falk, K., and Strominger, J. L., Superactivation of an immune response triggered by oligomerized T cell epitopes. Proc. Natl. Acad. Sci. USA 94, 14642-14647, 1997.
74. Alving, C. A., Koulchin, V., Glenn, G. M., and Rao, M., Liposomes as carriers of peptide antigens: Induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Immunol. Rev. 145, 1-31, 1995.
75. Ciernik, I. F., Berzofsky, J. A., and Carbone, D. P., Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J. Immunol. 156, 2369-2375, 1996.
76. Porgador, A., Staats, H. F., Faiola, B., Gilboa, E., and Palker, T. J., Intransal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide specific CTL and protection against tumor development in vivo. J. Immunol. 158, 834-841, 1997.
77. Noguchi, Y., Richards, E. C., Chen, Y.-T., and Old, L. J., Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. USA 92, 2219-2223, 1995.
78. Takahashi, H., Nakagawa, Y., Yokomuro, K., and Berzofsky, J. A., Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. Int. Immunol. 5, 849-857, 1992.